ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada. “

Several other analysts also recently commented on EPIX. ValuEngine downgraded shares of ESSA Pharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 7th. Bloom Burton lowered shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, September 12th. Finally, Dawson James reiterated a “buy” rating on shares of ESSA Pharma in a report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $4.75.

Shares of ESSA Pharma (NASDAQ EPIX) traded up 2.0134% on Tuesday, reaching $0.2888. The company’s stock had a trading volume of 46,995 shares. ESSA Pharma has a 1-year low of $0.26 and a 1-year high of $2.75. The company’s 50 day moving average is $0.29 and its 200-day moving average is $0.29. The stock’s market cap is $8.40 million.

COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Downgrades ESSA Pharma Inc. (EPIX) to Hold” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with's FREE daily email newsletter.